Latest / The Founder's Journey with Fexingo: First-Time Entrepreneurs, Failures, and Lessons Learned / The Founder Who Turned a Rejected Science Fair Project Into a 55M Biotech
Transcript
- Lucas: Priya Nair was fifteen years old when she submitted her science fair project on enzyme-coated nanoparticles to the regional competition. She didn't just lose. She was disqualified for submitting 'outside the spirit of a high school project.' The judges said it was too complex, too speculative, and frankly, they didn't believe she'd done the work herself. Luna: Ouch. That's the kind of rejection that makes most kids walk away from science entirely. Lucas: Yeah, and she almost did. She dropped the project, focused on school, went to college for biomedical engineering. But here's the thing — she kept the lab notebook. That notebook ended up in a box in her parents' garage for eight years. Luna: So the idea just sat there? Lucas: It sat there until her second year of grad school, when she was cleaning out that garage and found it. She flipped through it, and she realised something — the enzyme-nanoparticle concept she'd sketched out as a teenager was actually more advanced than what most labs were publishing at the time. She showed it to her advisor, who basically said, 'This is either genius or insane. Let's find out.' Luna: Her advisor didn't dismiss it. That's already a different outcome than the science fair judges. Lucas: Exactly. And that led to three years of refinement in the lab. They proved the nanoparticles could target specific cancer cells without affecting healthy tissue. By 2022, they had enough data to file a patent. But then came the next rejection — every venture capital firm they pitched said the same thing: 'This is just a science fair story. Where's the commercial viability?' Luna: It's fascinating how the same rejection pattern followed her from high school to the boardroom. Lucas: Right. And she almost gave in. She had an offer from a pharma company to buy the patent outright for $1.5 million. That would have been a life-changing sum for a grad student. But she decided to license it instead, keeping a royalty share and the right to develop her own company. Luna: That's a gutsy call. Most people would take the million and a half. Lucas: Most people would. But she believed in the platform. And that decision is what led to Enzolve Therapeutics. A year later, they raised a $12 million Series A from a healthcare-focused venture fund that specialises in 'orphan technologies' — ideas that got rejected early but had strong underlying science. Luna: So the fund's whole thesis is betting on rejected ideas? That's almost poetic. Lucas: It is. And it worked. By 2025, Enzolve was valued at $55 million, after a Series B led by the same fund. They're now in Phase 2 trials for a pancreatic cancer therapy that uses those same enzyme-coated nanoparticles she designed at fifteen. Luna: You know, this story makes me think about how many potentially world-changing ideas get discarded simply because the person behind them is too young, or too junior, or too outside the establishment. Priya's science fair judges weren't just rejecting a project — they were almost rejecting a future therapy. Lucas: That's the thing about early rejection. It can be a signal, but not always a useful one. The challenge is knowing which rejections are about you and which are about the system's inability to recognise something new. Priya's story is a case study in that. Luna: And she had to navigate that multiple times — science fair, then VCs, then the temptation to sell out. Each time, she chose to keep going. Lucas: Yeah. And it's worth noting that her path wasn't just about grit. She also had key enablers — her advisor, that orphan-tech fund. So it's not just 'believe in yourself.' It's also finding the right people who will believe in you when the rest of the world says no. Luna: Which is something we talk about a lot on this show. And it's also something that makes me grateful for the community that supports this podcast. We don't run ads, and that's intentional. A small group of listeners chips in monthly through buy me a coffee dot com slash fexingo, and that literally funds making episodes like this one. Lucas: Yeah, it's a simple model — listener-supported, no sponsors, no pressure. If these conversations have moved your work forward in some small way, that's the door. And if not, the next story is coming right up. Luna: Exactly. So back to Priya's story — after the Series B, she faced a new challenge. The clinical trial results were promising, but the pharma company that originally wanted to buy her patent came back with a new offer. This time, $20 million for an exclusive license. Lucas: And she turned that down too. Because by then, the data was strong enough that she believed the company could go public or get acquired for far more. She was betting on a billion-dollar outcome, not a twenty-million-dollar exit. Luna: That's a huge bet. She's essentially doubling down on her own science. Lucas: She is. And it's a calculated risk. The trial data shows a 40 percent reduction in tumor size in animal models, with minimal side effects. If that translates to humans, it's a blockbuster. But if the Phase 2 fails, the company could be worth zero. Luna: So she's essentially betting her entire career on these nanoparticles. Lucas: Yes. And it's a reminder that entrepreneurship, especially in biotech, is not for the faint of heart. The timeline is long, the capital requirements are huge, and the odds of success are low. But the potential impact is enormous. Luna: I wonder what she would say to her fifteen-year-old self now, the one who got disqualified from the science fair. Lucas: She actually addressed that in an interview last year. She said, 'I would tell her: That rejection isn't about your idea. It's about the judges' inability to see what you see. Keep the notebook. Trust the data.' And she did. Luna: That's powerful. Because most of us, when we get rejected, we internalise it. We think we're the problem. Lucas: Right. And Priya's story is a concrete example of how to separate the idea from the rejection. The idea was solid. The rejection was noise. But it took eight years and a garage cleanup to realise that. Luna: So what's the key lesson for someone listening who has a rejected idea sitting in a drawer somewhere? Lucas: I think it's this: Don't throw away the notebook. Don't delete the files. Store the idea in a way that you can rediscover it later, when you have more context, more resources, or a better network. Priya didn't actively work on that project for eight years, but she preserved it. And that preservation was the first step toward a $55 million company. Luna: That's a practical takeaway. It's not about relentlessly pursuing every idea — it's about keeping the ones that have genuine potential, even if the world says no at first. Lucas: Exactly. And it's also about recognising when the rejection is about timing or context, not about merit. The science fair judges weren't equipped to evaluate a PhD-level project. The VCs who said no weren't equipped to see a platform technology that would take a decade to mature. But Priya found the people who could see it. Luna: So finding the right audience for your idea is as important as the idea itself. Lucas: That's the second lesson. Don't just pitch to anyone who will listen. Find the investors, partners, or mentors who have a track record of backing ideas that others dismissed. That orphan-tech fund is a perfect example — they built their entire thesis around that gap. Luna: And now Priya Nair is a name to watch. If the Phase 2 trial succeeds, Enzolve could be one of the biggest biotech stories of the decade. Lucas: And if it doesn't, the story still matters. Because it shows that a rejected science fair project can spark a company, a patent, a clinical trial, and a valuation of $55 million. That's not failure. That's a long, nonlinear path to impact. Luna: It makes you wonder what other ideas are sitting in garages right now, waiting to be rediscovered. Lucas: That's the question that keeps founders going. And it's the question we'll keep exploring on this show.